Alzheimer Disease Clinical Trials in Orange, California

7 studies are recruiting for alzheimer disease in Orange, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

   The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who c…

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Local Institution - 2649, Orange, California

   Locations

   252 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06937229 on ClinicalTrials.gov

2. Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

   This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P…

   Stage

   Phase 2

   Ages

   55 to 80

   Site

   ATP Clinical Research, Inc., Orange, California

   Locations

   38 in total

   Run by

   Lighthouse Pharmaceuticals, Inc.

   See if you can join NCT06847321 on ClinicalTrials.gov

3. Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders

   The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older patients during hospital admission. The main objectives of the trial are t…

   Stage

   Not phased

   Ages

   70 and older

   Site

   Saddleback Medical Center, Orange, California

   Locations

   7 in total

   Run by

   University of Michigan

   See if you can join NCT05929703 on ClinicalTrials.gov

4. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

   This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.

   Stage

   Phase 2

   Ages

   55 and older

   Site

   ATP Clinical Research, Orange, California

   Locations

   67 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06540833 on ClinicalTrials.gov

5. A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

   The primary purpose of this study is to evaluate the safety and tolerability of Zunveyl® over 12 weeks of routine clinical use in adults with mild to moderate Alzheimer's disease.

   Stage

   Phase 4

   Ages

   50 and older

   Site

   ATP Clinical Research, Inc - Orange, Orange, California

   Locations

   14 in total

   Run by

   Alpha Cognition, Inc

   See if you can join NCT07633470 on ClinicalTrials.gov

6. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

   The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Local Institution - 1001, Orange, California

   Locations

   293 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT06585787 on ClinicalTrials.gov

7. Trial-Ready Cohort-Down Syndrome (TRC-DS)

   The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 550 participants in total including co-enrolled in the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-D…

   Stage

   Not phased

   Ages

   25 to 55

   Site

   University of California, Irvine School of Medicine, Co-Enrolling through ABC-DS Only, Orange, California

   Locations

   22 in total

   Run by

   University of Southern California

   See if you can join NCT04165109 on ClinicalTrials.gov